EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20–mutant NSCLC: case report

Basil Dabbah, Roni Gillis, Jaber Salim, Adar Yaacov, Bar Cohen, Areen Abu Remilah, Yehonatan Turner, Noam Asna, Nir Peled

Frontiers in Oncology · 06.08.2026 · 16

DOI: 10.3389/fonc.2026.1812440 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 06.08.2026. Verfasst von Basil Dabbah und 8 weiteren Autor:innen. Beteiligte Einrichtung: Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

EGFR exon 20 insertion mutations represent a distinct subset of non–small cell lung cancer (NSCLC) with limited sensitivity to earlier-generation EGFR tyrosine kinase inhibitors (TKIs). CLN081 (zipalertinib; TAS6417) is a novel covalent EGFR TKI under development with activity against EGFR exon 20 insertion variants. We report the case of a 44-year-old man with stage IVB lung adenocarcinoma harboring an EGFR exon 20 insertion mutation who received multiple lines of systemic therapy, including CLN081. After eight months of treatment with CLN081, liquid biopsy revealed the emergence of a secondary EGFR C797S mutation (p.Cys797Ser; variant allele frequency [VAF] 0.05%), concurrent with a reduction in the exon 20 insertion allele frequency from 35.1% to 0.5%, accompanied by disease progression. Although C797S-mediated resistance has been hypothesized and demonstrated in preclinical models of CLN081 exposure, this represents, to our knowledge, the first reported in vivo identification of an EGFR C797S resistance mutation following CLN081 therapy. This case provides clinically relevant insight into resistance mechanisms associated with emerging EGFR exon 20–targeted therapies.

Schlagwörter

Stichwörter der Autor:innen

CLN081EGFR C797SEGFR exon 20 insertionacquired resistancecase reportliquid biopsynon–small cell lung cancer

Autor:innen und Institutionen

  • Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel.
  • Department of Nuclear Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.

Zitieren

APA

Dabbah, B., Gillis, R., Salim, J., Yaacov, A., Cohen, B., Abu Remilah, A., Turner, Y., Asna, N., & Peled, N. (2026). Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20–mutant NSCLC: case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1812440

Vancouver

Dabbah B, Gillis R, Salim J, Yaacov A, Cohen B, Abu Remilah A, et al. Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20–mutant NSCLC: case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1812440

BibTeX
@article{Dabbah2026,
  author = {Dabbah, Basil and Gillis, Roni and Salim, Jaber and Yaacov, Adar and Cohen, Bar and Abu Remilah, Areen and Turner, Yehonatan and Asna, Noam and Peled, Nir},
  title = {Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20–mutant NSCLC: case report},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1812440}
}
Kostenlos starten →